Perspective Therapeutics (CATX) Interest Coverage Ratio (QoQ) (2010 - 2026)
Powered by 
Analysis
Perspective Therapeutics (CATX) Interest Coverage Ratio (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Perspective Therapeutics | 358.23 Mn | 358.23 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -53.00% |
| Jun 30, 2025 | -18.44% |
| Mar 31, 2025 | -127.68% |
| Dec 31, 2024 | 328.18% |
| Sep 30, 2024 | 56.45% |
| Jun 30, 2024 | -38.28% |
| Mar 31, 2024 | 7.82% |
| Dec 31, 2023 | 30.14% |
| Sep 30, 2023 | -85.64% |
| Jun 30, 2023 | 30.82% |
| Sep 30, 2015 | -261.26% |
| Jun 30, 2015 | 106.78% |
| Sep 30, 2014 | 98.57% |
| Dec 31, 2013 | -628.91% |
| Sep 30, 2013 | 99.84% |
| Sep 30, 2012 | -1,101,216.80% |
| Jun 30, 2012 | 92.73% |
| Mar 31, 2012 | 12.65% |
| Dec 31, 2011 | 97.72% |
| Sep 30, 2011 | -35,255.50% |